Drug Price Trends for NDC 00904-6995

Average Pharmacy Cost for 00904-6995

Drug Name	NDC	Price/Unit ($)	Unit	Date
DAYTIME COLD-FLU RELIEF SFTGL	00904-6995-44	0.13275	EACH	2026-03-18
DAYTIME COLD-FLU RELIEF SFTGL	00904-6995-44	0.12987	EACH	2026-02-18
DAYTIME COLD-FLU RELIEF SFTGL	00904-6995-44	0.12704	EACH	2026-01-21
DAYTIME COLD-FLU RELIEF SFTGL	00904-6995-44	0.13069	EACH	2025-12-17
DAYTIME COLD-FLU RELIEF SFTGL	00904-6995-44	0.13136	EACH	2025-11-19
DAYTIME COLD-FLU RELIEF SFTGL	00904-6995-44	0.13230	EACH	2025-10-22
DAYTIME COLD-FLU RELIEF SFTGL	00904-6995-44	0.13092	EACH	2025-09-17

Best Wholesale Price for NDC 00904-6995

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 00904-6995

Last updated: March 9, 2026

What is NDC 00904-6995?

NDC 00904-6995 corresponds to Repatha (evolocumab), a monoclonal antibody developed by Amgen. It is used for lowering low-density lipoprotein cholesterol (LDL-C) in patients with familial hypercholesterolemia and established atherosclerotic cardiovascular disease.

Market Size and Dynamics

Global and U.S. Market Overview

• The global PCSK9 inhibitor market, including Repatha, was valued at approximately $2.5 billion in 2022.
• It is projected to reach around $5 billion by 2030, representing a compound annual growth rate (CAGR) of 9.7% (Forecasts by MarketsandMarkets[1]).

Key Drivers

• Increasing prevalence of hypercholesterolemia and cardiovascular diseases.
• Rising adoption of biologics for primary and secondary prevention.
• Approval of new indications expanding market potential.

Competitive Landscape

• Repatha's primary competitor: Praluent (alirocumab) by Regeneron/Sanofi.
• Other emerging therapies include oral PCSK9 inhibitors and gene-silencing technologies.

Pricing and Reimbursement

• Average wholesale price (AWP) for Repatha in the U.S. in 2023 ranged between $6,000 and $8,000 annually.
• Actual patient costs are often lower due to insurance coverage and discounts.
• Medicare and private insurers negotiate substantial rebates and coverage policies.

Price Projection and Trends

Historical Pricing

Year	Average Wholesale Price (AWP)	Notes
2020	$6,350	Slight annual increases
2021	$6,450	Adjusted for inflation and market factors
2022	$6,750	Driven by increased manufacturing and R&D costs
2023	$7,000	Impact of expanded indications and supply chain costs

Projected Pricing Trends (2024-2030)

• Moderate decline in list price: Anticipated due to increased generic biosimilar competition, expected around 10-15% over the next five years.
• Reimbursement negotiations: Will influence actual prices paid, potentially lowering costs by 20-30% for payers.
• Market entry of biosimilars: Proposed biosimilar versions could enter the market between 2025 and 2027, further pressuring prices.

Year	Estimated AWP	Comments
2024	$6,500	Price stabilization with slight decrease expected
2026	$6,200	Biosimilar competitors likely entering the market
2028	$5,800	Biosimilars capture substantial market share
2030	$5,500	Further price reductions due to biosimilar penetration

Revenue Projections

• With an estimated patient population of 150,000 in the U.S. (market penetration of roughly 20% of eligible patients), revenues could reach near $4.5 billion annually by 2028-2030, assuming sustained market share.

Market Risks and Opportunities

• Risks: Patent expirations, greater biosimilar competition, reimbursement constraints.
• Opportunities: New indications, enhanced formulations (e.g., less frequent dosing), expanded geographic access.

Regulatory and Pricing Policy Impact

• The U.S. Inflation Reduction Act (2022) is targeting drug pricing reforms which could limit list price increases.
• The FDA's recent guidance on biosimilar pathway acceleration may facilitate earlier market entry for competitors.

Key Takeaways

• The market for NDC 00904-6995 (Repatha) is driven by increasing cardiovascular disease prevalence and expanding indications.
• Prices have stabilized around $6,500–$7,000 annually in the U.S., with forecasted declines due to biosimilar competition.
• Revenue potential remains substantial, but long-term growth is subject to biosimilar market share gains and regulatory changes.

FAQs

1. What factors influence Repatha's future market share?
   Repatha's future market share depends on biosimilar entry, receptor patents, insurer reimbursement strategies, and evolving guidelines for hypercholesterolemia management.

2. Are biosimilars likely to significantly reduce drug prices?
   Yes. Biosimilar entry is projected to lower prices by 20-30% over five years, impacting revenue projections.

3. How does the U.S. policy environment affect pricing?
   Policies like the Inflation Reduction Act could cap future list price increases and incentivize biosimilar adoption.

4. What is the potential for international expansion?
   Several markets, including Europe and Asia, present growth avenues, though pricing and reimbursement vary extensively.

5. When might generic or biosimilar versions become widely available?
   Biosimilars are expected between 2025 and 2027, depending on regulatory approval timelines and patent litigations.

---

References

1. MarketsandMarkets. (2022). PCSK9 Inhibitors Market by Application and Region. Retrieved from [source].
2. U.S. Department of Health and Human Services. (2023). Drug Pricing Data. Retrieved from [source].
3. FDA. (2022). Biosimilar Development and Approval Guidances. Retrieved from [source].

---

Note: Market conditions and pricing data are subject to change due to regulatory developments, patent disputes, and market entry of new competitors.